(en) K Drlica et X Zhao, « DNA gyrase, topoisomerase IV, and the 4-quinolones », Microbiol Mol Biol Rev, vol. 61, no 3, , p. 377-392 (PMID9293187, PMCID232616, lire en ligne)
(en) T Akasaka, M Tanaka, A Yamaquchi et K Sato, « Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. », Antimicrob Agents Chemother, vol. 45, no 8, , p. 2263-2268 (PMID11451683, PMCIDPMC90640, DOI10.1128/AAC.45.8.2263-2268.2001, lire en ligne)
(en) Y Fu, W Zhang, H Wang, S Zhao, Y Chen, F Meng, Y Zhang, H Xu, X Chen et F Zhang, « Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. », BMC Infect. Dis., vol. 13, no 8, (PMID23295059, PMCIDPMC3576228, DOI10.1186/1471-2334-13-8, lire en ligne)
(en) JA Bohnert et WV Kem, « Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. », Antimicrob Agents Chemother, vol. 49, no 2, , p. 849-852 (PMID15673787, PMCIDPMC547223, DOI10.1128/AAC.49.2.849-852.2005, lire en ligne)
(en) N Mor, J Vanderkolk et L Heifets, « Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. », Antimicrob Agents Chemother, vol. 38, no 5, , p. 1161-1164 (PMID8067756, PMCIDPMC188169, lire en ligne)
(en) KP Fu, SC Lafredo, B Foleno, DM Isaacson, JF Barrett, AJ Tobia et ME Rosenthale, « In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. », Antimicrob Agents Chemother, vol. 36, no 4, , p. 860-866 (PMID1503449, PMCIDPMC189464, lire en ligne)
(en) M Tanakaa, T Kurata, C Fujisawa, Y Ohshima, H Aoki, O Okazaki et H Hakusui, « Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. », Antimicrob Agents Chemother, vol. 37, no 10, , p. 2173-2178 (PMID8257141, PMCIDPMC192246, lire en ligne)
(en) K Drlica et X Zhao, « DNA gyrase, topoisomerase IV, and the 4-quinolones », Microbiol Mol Biol Rev, vol. 61, no 3, , p. 377-392 (PMID9293187, PMCID232616, lire en ligne)
(en) T Akasaka, M Tanaka, A Yamaquchi et K Sato, « Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. », Antimicrob Agents Chemother, vol. 45, no 8, , p. 2263-2268 (PMID11451683, PMCIDPMC90640, DOI10.1128/AAC.45.8.2263-2268.2001, lire en ligne)
(en) Y Fu, W Zhang, H Wang, S Zhao, Y Chen, F Meng, Y Zhang, H Xu, X Chen et F Zhang, « Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. », BMC Infect. Dis., vol. 13, no 8, (PMID23295059, PMCIDPMC3576228, DOI10.1186/1471-2334-13-8, lire en ligne)
(en) JA Bohnert et WV Kem, « Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. », Antimicrob Agents Chemother, vol. 49, no 2, , p. 849-852 (PMID15673787, PMCIDPMC547223, DOI10.1128/AAC.49.2.849-852.2005, lire en ligne)
